Envisagenics Awarded $2M+ NCI SBIR Grant to Expand AI-Driven RNA Splicing Analysis Capabilities Across Oncology Portfolio
Envisagenics has received a $2 million grant from the National Cancer Institute to advance its AI-driven RNA splicing analysis platform. The funding will support the development of machine learning tools to identify novel cancer therapeutic targets.
Why it matters
This grant accelerates the integration of AI into precision oncology, potentially leading to more effective cancer treatments.
Funding will advance translational readiness across Envisagenics’ cancer-specific programs for internal development and strategic partnering
NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Envisagenics, Inc. , an AI-driven RNA splicing therapeutics company, announced today that it has been awarded a Small Business Innovation Research (SBIR) Direct to Phase II grant from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH).
The award will provide more than $2 million over two years to support further development and commercialization of SpliceCore®, including SpliceDisco™, a new machine learning algorithm designed to connect cancer-specific therapeutic targets with the splicing mechanisms that drive disease. With this capability, Envisagenics can prioritize targets with strong biological rationale and therapeutic potential.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in